Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Metabolic disease drug discovery- "hitting the target" is easier said than done.

Moller DE.

Cell Metab. 2012 Jan 4;15(1):19-24. doi: 10.1016/j.cmet.2011.10.012.

2.

Essay for the 2011 CIHR/CMAJ award: glucagon-like peptides for metabolic and gastrointestinal disorders.

Drucker DJ.

CMAJ. 2012 Feb 7;184(2):E153-4. doi: 10.1503/cmaj.112127. Epub 2012 Jan 23. No abstract available.

3.
4.

[DPP-4 inhibitors, GLP-1 receptor agonists].

Hamasaki A, Inagaki N.

Nihon Rinsho. 2011 Jan;69 Suppl 1:654-61. Review. Japanese. No abstract available.

PMID:
21766677
5.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. Review.

PMID:
19801361
6.

Efficacy and safety of incretin based therapies: clinical trial data.

White J.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S30-40. doi: 10.1331/JAPhA.2009.09079. Review.

PMID:
19801363
7.

Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).

Thornberry NA, Gallwitz B.

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):479-86. doi: 10.1016/j.beem.2009.03.004.

PMID:
19748065
8.

Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.

Maezaki H, Banno Y, Miyamoto Y, Moritoh Y, Asakawa T, Kataoka O, Takeuchi K, Suzuki N, Ikedo K, Kosaka T, Sasaki M, Tsubotani S, Tani A, Funami M, Yamamoto Y, Tawada M, Aertgeerts K, Yano J, Oi S.

Bioorg Med Chem. 2011 Aug 1;19(15):4482-98. doi: 10.1016/j.bmc.2011.06.032. Epub 2011 Jul 7. Erratum in: Bioorg Med Chem. 2011 Sep 15;19(18):5742. Moritou, Yuusuke [corrected to Moritoh, Yusuke].

PMID:
21741847
9.

GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.

Gallwitz B.

Handb Exp Pharmacol. 2011;(203):53-74. doi: 10.1007/978-3-642-17214-4_3. Review.

PMID:
21484567
10.

Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors.

Davidson JA.

Cleve Clin J Med. 2009 Dec;76 Suppl 5:S28-38. doi: 10.3949/ccjm.76.s5.05. Review.

11.

Incretin-based therapies for type 2 diabetes mellitus.

Lovshin JA, Drucker DJ.

Nat Rev Endocrinol. 2009 May;5(5):262-9. doi: 10.1038/nrendo.2009.48. Review.

PMID:
19444259
12.

The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.

Deng J, Peng L, Zhang G, Lan X, Li C, Chen F, Zhou Y, Lin Z, Chen L, Dai R, Xu H, Yang L, Zhang X, Hu W.

Eur J Med Chem. 2011 Jan;46(1):71-6. doi: 10.1016/j.ejmech.2010.10.016. Epub 2010 Oct 26.

PMID:
21106276
13.

Type 2 diabetes: an expanded view of pathophysiology and therapy.

Unger J, Parkin CG.

Postgrad Med. 2010 May;122(3):145-57. doi: 10.3810/pgm.2010.05.2152. Review.

PMID:
20463424
14.

[Therapeutic indications of incretin-related derivatives and other oral hypoglycemic agents].

Katsuno T, Miyagawa J.

Nihon Rinsho. 2012 May;70 Suppl 3:693-8. Japanese. No abstract available.

PMID:
22768600
15.

The future of incretin-based therapy: novel avenues--novel targets.

Ahrén B.

Diabetes Obes Metab. 2011 Oct;13 Suppl 1:158-66. doi: 10.1111/j.1463-1326.2011.01457.x. Review.

PMID:
21824270
16.

Type 2 diabetes: epidemiology and treatment, pathophysiology, new therapeutics, and the evolving role of the pharmacist.

Campbell RK, Neumiller JJ, White J, Sisson E, Kuhn C.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S2. doi: 10.1331/JAPhA.2009.09537. No abstract available.

PMID:
19801362
17.

[Innovations in the treatment of type 2 diabetes mellitus: use of incretins].

Dedov II, Shestakova MV, Sukhareva OIu.

Ter Arkh. 2010;82(10):5-10. Russian.

PMID:
21341455
18.

Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.

Moore KB, Saudek CD.

Am J Ther. 2008 Sep-Oct;15(5):484-91. doi: 10.1097/MJT.0b013e3180ed42dc. Review.

PMID:
18806525
19.
20.

RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.

Singh S, Roy S, Sethi S, Benjamin B, Sundaram S, Khanna V, Kandalkar SR, Pal C, Kant R, Patra AK, Rayasam G, Mittra S, Saini KS, Paliwal J, Chugh A, Ahmed S, Sattigeri J, Cliff I, Ray A, Bansal VS, Bhatnagar PK, Davis JA.

Eur J Pharmacol. 2011 Feb 10;652(1-3):157-63. doi: 10.1016/j.ejphar.2010.06.001. Epub 2010 Jun 9. Erratum in: Eur J Pharmacol. 2011 Mar 25;655(1-3):121. multiple author names added.

PMID:
20540938
Items per page

Supplemental Content

Write to the Help Desk